Lifecore Biomedical, Inc. (NASDAQ:LFCR – Get Rating) – Equities research analysts at Barrington Research boosted their Q3 2024 EPS estimates for Lifecore Biomedical in a research report issued to clients and investors on Friday, June 2nd. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of $0.21 per share for the quarter, up from their prior estimate of $0.19. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.87) per share.
Lifecore Biomedical (NASDAQ:LFCR – Get Rating) last posted its quarterly earnings data on Thursday, March 16th. The company reported ($0.24) earnings per share (EPS) for the quarter. Lifecore Biomedical had a negative net margin of 40.38% and a negative return on equity of 21.34%. The business had revenue of $38.80 million during the quarter.
Lifecore Biomedical Trading Down 1.2 %
Shares of LFCR stock opened at $8.15 on Monday. The stock has a market cap of $247.11 million, a P/E ratio of -2.40 and a beta of 1.03. The stock has a 50 day simple moving average of $4.87 and a 200 day simple moving average of $5.88. Lifecore Biomedical has a 1 year low of $1.52 and a 1 year high of $11.95.
Institutional Investors Weigh In On Lifecore Biomedical
A hedge fund recently bought a new stake in Lifecore Biomedical stock. Prelude Capital Management LLC bought a new stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR – Get Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 21,295 shares of the company’s stock, valued at approximately $80,000. Prelude Capital Management LLC owned approximately 0.07% of Lifecore Biomedical as of its most recent filing with the SEC.
About Lifecore Biomedical
Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.
Featured Stories
- Get a free copy of the StockNews.com research report on Lifecore Biomedical (LFCR)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
